var data={"title":"Vitamin D2 (ergocalciferol): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin D2 (ergocalciferol): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6121?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-drug-information\" class=\"drug drug_general\">see &quot;Vitamin D2 (ergocalciferol): Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin D2 (ergocalciferol): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166127\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Calcidol [OTC];</li>\n      <li>Calciferol [OTC];</li>\n      <li>Drisdol [DSC];</li>\n      <li>Drisdol [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166128\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>D-Forte;</li>\n      <li>Erdol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058419\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin D Analog</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Fat Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442452\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mcg = 40 USP units </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate Intake (AI):</b> Oral: 400 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency, prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations (Abrams 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;1.5 kg: 200 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;1.5 kg: 200 units/day; increase dose to 400 units/day when tolerating full enteral nutrition; maximum daily dose: 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Neonates &lt;1 kg: Oral: 150 to 400 units/kg/day (Greer 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: Breast-fed (fully or partially): Oral: 400 units/days beginning in the first few days of life; continue supplementation until infant is weaned to &ge;1,000 mL/day vitamin D-fortified formula (Golden 2014; Wagner 2008)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency, treatment:</b> Oral: <b>Note:</b> In addition to calcium and phosphorus supplementation: 2,000 units daily or  50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily (Golden 2014; Holick 2011). <b>Note:</b> For patients at high risk of fractures, a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058412\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-drug-information\" class=\"drug drug_general\">see &quot;Vitamin D2 (ergocalciferol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mcg = 40 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate Intake (AI):</b> Oral: Infants: 400 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended Daily Allowance (RDA):</b> Oral: Children and Adolescents: 600 units/day (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D deficiency, prevention:</b> (Wagner 2008): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Breast-fed infants (fully or partially): Oral: 400 units/day beginning in the first few days of life. Continue supplementation until infant is weaned to &ge;1,000 mL/day or 1 qt/day of vitamin D-fortified formula or whole milk (after 12 months of age)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Formula-fed infants ingesting &lt;1,000 mL of vitamin D-fortified formula or milk: Oral: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents without adequate intake: Oral: 400 units/day. <b>Note:</b> Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications): Higher doses may be required. Use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D deficiency, treatment:</b> <b>Note:</b> In addition to calcium and phosphorus supplementation (Holick 2011; Golden 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Oral: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level &gt; 20ng/mL); followed by a maintenance dose of 400 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Oral: 2,000 units daily or 50,000 units once weekly for 6 to 8 weeks to achieve a serum 25(OH)D level &gt; 20 ng/ml); followed by a maintenance dose of 600 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications glucocorticoids, HIV medications and antifungals such as ketoconazole, obesity): Oral: Higher doses (2 to 3 times higher) may be required; doses of at least 6,000 to 10,000 units daily until serum 25(OH)D level &gt;30 ng/mL, followed by a maintenance dose of 3,000 to 6,000 units daily have been suggested (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> If poor compliance, single high-dose administration of 100,000 to 600,000 units over 1 to 5 days followed by maintenance dosing; intermittently repeating (usually every 3 months) may be needed if poor compliance continues with maintenance dosing (Misra 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D insufficiency or deficiency associated with CKD (stages 2-5, 5D); serum 25 hydroxyvitamin D (25[OH]D) level &lt;30 ng/mL:</b> (K/DOQI Guidelines, 2009): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: 2,000 units/day for 3 months or 50,000 units every month for 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level 5-15 ng/mL: Infants, Children, and Adolescents: 4,000 units/day for 12 weeks or 50,000 units every other week for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum 25(OH)D level &lt;5 ng/mL: Infants, Children, and Adolescents: 8,000 units/day for 4 weeks then 4,000 units/day for 2 months for total therapy of 3 months or 50,000 units/week for 4 weeks followed by 50,000 units 2 times monthly) for a total therapy of 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose [once repletion accomplished; serum 25(OH)D level &gt;30 ng/mL]: Infants, Children, and Adolescents: 200 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoparathyroidism:</b> Oral: Infants, Children, and Adolescents: 50,000 to 200,000 units daily with calcium supplements</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D-resistant rickets; treatment:</b> Infants, Children, and Adolescents: Oral: 12,000 to 500,000 units daily in combination with calcium supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dietary Reference Intake for Vitamin D: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults 19 to 70 years: RDA: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female: Pregnancy/lactating: RDA: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoparathyroidism:</b> Oral: 1.25 to 5 mg/day (50,000 to 200,000 units/day) with calcium supplements</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin D-resistant rickets:</b> Oral: 12,000 to 500,000 units/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166109\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Drisdol: 50,000 units [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), soybean oil, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcidol: 8000 units/mL (60 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calciferol: 8000 units/mL (60 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Drisdol: 8000 units/mL (60 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8000 units/mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 2000 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166094\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058423\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral: May be administered without regard to meals; for oral liquid, use accompanying dropper for dosage measurements</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166125\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058422\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of refractory rickets, familial hypophosphatemia, and hypoparathyroidism (All indications: Capsules: FDA approved in pediatric patients [age not specified] and adults): Vitamin D dietary supplement (OTC product: Oral solution and Tablets: FDA approved in all ages); has also been used to treat vitamin D deficiency and insufficiency in patients with chronic kidney disease (CKD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166164\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calciferol may be confused with calcifediol, calcitriol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Drisdol may be confused with Drysol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ergocalciferol may be confused with alfacalcidol, cholecalciferol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 units per dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166162\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Endocrine &amp; metabolic: Hypervitaminosis D</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166116\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypercalcemia; malabsorption syndrome; abnormal sensitivity to the toxic effects of vitamin D; hypervitaminosis D</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the manufacturer&rsquo;s labeling lists use in malabsorption syndrome as contraindicated, when dosed appropriately, ergocalciferol may be used in these patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for vitamin D analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166098\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperphosphatemia: Normal serum phosphorous concentrations  must be maintained in patients treated for hyperphosphatemia to prevent metastatic calcification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoparathyroidism: Concomitant treatment with intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may also be required when treating hypoparathyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obesity: Adults with a BMI &gt;30 kg/m<sup>2</sup> are at high risk for vitamin D deficiency due to storage of vitamin D in adipose tissue.  Doses higher than the RDA may be required, but must be carefully monitored to avoid toxicity (Holick, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:  Metabolism of vitamin D may be altered in patients with chronic kidney disease. Supplementation with ergocalciferol may be needed; close monitoring is required (KDOQI, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rickets: The range between therapeutic and toxic doses is narrow in vitamin D-resistant rickets; adjust dose based on clinical response to avoid toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Oral solutions may contain propylene glycol; toxicities may occur if large doses of vitamin D are required. Alternate dosage forms/products should be used (Misra, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Products may contain tartrazine, which may cause allergic reactions in certain individuals. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Adequate calcium supplementation is required; calcium and phosphorous levels must be monitored during therapy. All sources of vitamin D (eg, dietary supplements, fortified foods, medication) should be evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxicity: Effects of vitamin D can last &ge;2 months after therapy is discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535319\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299278\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166103\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13274&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166105\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5075482\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. The ergocalciferol (vitamin D<sub>2</sub>) metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra, 2008; Wagner, 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra, 2008; Wagner, 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG, 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1000 to 2000 units/day until more safety data is available (ACOG, 2011; Holick, 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058418\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone-mineral status to evaluate. If vitamin D supplement is required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral-status should be monitored every 6 months until normal.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic kidney disease: Monitor serum 25(OH)D, corrected total calcium and phosphorus levels 1 month following initiation of therapy, every 3 months during therapy and with any vitamin D dose change; alkaline phosphatase, BUN, bone x-ray (hypoparathyroidism) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058421\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin D status may be determined by serum 25(OH) D levels (Misra 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe deficiency: &le;5 ng/mL (12.5 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deficiency: 15 ng/mL (37.5 nmol/L)     </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insufficiency: 15 to 20 ng/mL (37.5 to 50 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sufficiency: 20 to 100 ng/mL (50 to 250 nmol/L)*</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excess: &gt;100 ng/mL (250 nmol/L)**</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intoxication: 150 ng/mL (375 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">*Based on adult data a level of &gt;32 ng/mL (80 nmol/L) is desirable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">**Arbitrary designation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Target  serum 25(OH) D: &gt;30 ng/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166097\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ergocalciferol (vitamin D<sub>2</sub>) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166115\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 10 to 24 hours; Maximum effect: ~1 month following daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D ~4 hours (Holick, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (IOM, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058428\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1.25 mg ergocalciferol provides 50,000 units of vitamin D activity; 1 drop of 8000 units/mL = 200 units (40 drops = 1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Chronic kidney disease (CKD) (KDIGO 2013; KDOQI 2002): Children &ge;2 years, Adolescents, and Adults: GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &ge;3 months; stages of CKD are described below: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 2: Kidney damage with mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 3: Moderate decrease in GFR; GFR 30 to 59 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">CKD Stage 5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5686151\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcidol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $99.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calciferol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $206.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ergocalciferol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $88.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166120\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adekon (MX);</li>\n      <li>Aderowest (MX);</li>\n      <li>AFI-D2 forte (NO);</li>\n      <li>Aquasol AD (MX);</li>\n      <li>Axed (MX);</li>\n      <li>Biocatines D2 (ES);</li>\n      <li>Calciferol (CZ);</li>\n      <li>Calciferol BD (TH);</li>\n      <li>D-forte (FI);</li>\n      <li>DePURA (BR);</li>\n      <li>Devitol (AT, FI);</li>\n      <li>Endo-D (IT);</li>\n      <li>Ergosterina Irradiata (IT);</li>\n      <li>Farmobion D2 (IT);</li>\n      <li>Infadin (CZ);</li>\n      <li>Jekovit (FI);</li>\n      <li>One-Alpha (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Ostelin (AU, IT);</li>\n      <li>Pharmaton Complex (MX);</li>\n      <li>Raquiferol (AR);</li>\n      <li>Raquiferol BC (PY);</li>\n      <li>Raquiferol D2 (PE);</li>\n      <li>Sterogyl (BE, LU);</li>\n      <li>Sterogyl-15 (FR);</li>\n      <li>Uvesterol D (FR);</li>\n      <li>Vigantol (ES);</li>\n      <li>Vigantolo (IT);</li>\n      <li>Vitamina D2 Salf (IT);</li>\n      <li>Vitaminol (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/23629620 /pubmed\" target=\"_blank\" id=\"23629620 \">23629620 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drisdol capsule (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drisdol solution (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golden NH, Abrams SA, Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-1243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/25266429 /pubmed\" target=\"_blank\" id=\"25266429 \">25266429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline (published correction appears in <i>J Clin Endocrinol Metab</i>. 2011;96[12]:3908). <i>J Clin Endocrinol Metab</i>. 2011;96(7):1911-1930. doi: 10.1210/jc.2011-0385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/21646368/pubmed\" target=\"_blank\" id=\"21646368\">21646368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holick MF, &ldquo;Vitamin D Deficiency,&rdquo; <i>N Engl J Med</i>, 2007, 357(3):266-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/17634462/pubmed\" target=\"_blank\" id=\"17634462\">17634462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. Washington, DC: The National Academies Press; 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease,&quot; <i>Am J Kidney Dis</i>, 2002, 39(2 Suppl 1):46-75.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Work Group, &quot;KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. Executive Summary,&quot; <i>Am J Kidney Dis</i>, 2009, 53(3 Suppl 2):S11-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19231749/pubmed\" target=\"_blank\" id=\"19231749\">19231749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, et al, &quot;Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,&quot; <i>Pediatrics</i>, 2008, 122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Osteoporosis Foundation (NOF). Clinician&rsquo;s guide to prevention and treatment of osteoporosis. Washington, DC, 2014. Available at http://nof.org/hcp/resources/913</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez CP, &ldquo;Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(11): 763-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/14580225/pubmed\" target=\"_blank\" id=\"14580225\">14580225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stechschulte SA, Kirsner RS, and Federman DG, &ldquo;Vitamin D: Bone and Beyond, Rationale and Recommendations for Supplementation,&rdquo; <i>Am J Med</i>, 2009, 122(9):793-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19699370/pubmed\" target=\"_blank\" id=\"19699370\">19699370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding, et al, &quot;Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents,&quot; <i>Pediatrics</i>, 2008, 122(5):1142-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/18977996/pubmed\" target=\"_blank\" id=\"18977996\">18977996</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13274 Version 140.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166127\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166128\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058419\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442452\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058412\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166109\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F166094\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058423\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F166125\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058422\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F166164\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166162\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166116\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166098\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535319\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299278\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166103\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F166105\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5075482\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058418\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1058421\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166097\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F166115\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058428\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5686151\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F166120\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13274|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-d2-ergocalciferol-drug-information\" class=\"drug drug_general\">Vitamin D2 (ergocalciferol): Drug information</a></li><li><a href=\"topic.htm?path=vitamin-d2-ergocalciferol-patient-drug-information\" class=\"drug drug_patient\">Vitamin D2 (ergocalciferol): Patient drug information</a></li></ul></div></div>","javascript":null}